Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.

Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of direct reduction in trabecular outflow resistance in addition to a decrease in episcleral venous pressure and aqueous humor production. The efficacy of netarsudil has been shown in animal studies and human clinical trials.

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% - an observational switch study.

Purpose: The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.01% solution in patients with primary open-angle glaucoma (POAG), who were switched from bimatoprost 0.03% solution, compared to patients with POAG who continued on bimatoprost 0.

Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.

Objective: The aim of this study was to compare symptoms and anterior segment tolerability with short-term (3-day) administration of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.

Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost.

Purpose: The aim of this study was to study long-term intraocular pressure (IOP) lowering following a switch to bimatoprost in patients with open-angle glaucoma (OAG) not at target IOP while on latanoprost either as monotherapy or as polytherapy with other topical adjunctive agents.

Methods: A retrospective review of OAG patients, with <20% IOP lowering from pretreatment baseline while on latanoprost either as monotherapy or in combination with adjunctive agents who were switched to bimatoprost, was conducted. Main outcome measures were mean IOP at 6, 12, and 24 months following the switch to bimatoprost and percent IOP lowering from baseline IOP before the switch.

Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost.

Purpose: To compare the 12-hour efficacy and safety of dorzolamide/timolol fixed combination (DTFC) dosed twice daily versus latanoprost dosed every evening following a timolol run-in in primary open-angle glaucoma patients.

Methods: Following a 6-week timolol run-in patients were randomized to either DTFC or latanoprost for 6 weeks and then changed to the opposite treatment for 6 weeks. At the end of the run-in, and the end of each treatment period, the intraocular pressure (IOP) was measured every 2 hours between 8:00 AM and 8:00 PM.